Literature DB >> 3994749

Glucuronidation and sulfation in the rat in vivo. The role of the liver and the intestine in the in vivo clearance of 4-methylumbelliferone.

G J Mulder, S Brouwer, J G Weitering, E Scholtens, K S Pang.   

Abstract

The role of the liver in the conjugation of 4-methylumbelliferone (4MU), mainly glucuronidation, was investigated in the rat in vivo. The liver extracted 4MU almost completely (97%) during steady-state infusion, as measured by the difference between 4MU concentration in portal and hepatic venous blood. Previously, it was shown that the intestinal region extracts 40% of the 4MU of the incoming arterial blood. The liver and the gastrointestinal region are so efficient that their conjugation activity can account for total body clearance of 4MU (50-60 ml/min per kg). These results and other evidence on extrahepatic conjugation of phenolic substrates suggest that glucuronidation may be limited to the liver, (the kidney) and the gastrointestinal region, while sulfation may occur more widespread throughout the body. Protein binding studies showed the sulfate conjugate to be even more protein-bound than unconjugated 4MU, while 4MU glucuronide was much less bound to rat plasma proteins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994749     DOI: 10.1016/0006-2952(85)90513-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  The bioavailability and nonlinear clearance of (-)-carbovir in the rat.

Authors:  S H Huang; R P Remmel; C L Zimmerman
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

2.  Contribution of rat intestinal metabolism to the xenobiotics clearance.

Authors:  Mahmud Kajbaf; Raffaella Ricci; Serenella Zambon; Stefano Fontana
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-06-20       Impact factor: 2.441

3.  4-Methylumbelliferyl glucuronide contributes to hyaluronan synthesis inhibition.

Authors:  Nadine Nagy; Irina Gurevich; Hedwich F Kuipers; Shannon M Ruppert; Payton L Marshall; Bryan J Xie; Wenchao Sun; Andrey V Malkovskiy; Jayakumar Rajadas; Maria Grandoch; Jens W Fischer; Adam R Frymoyer; Gernot Kaber; Paul L Bollyky
Journal:  J Biol Chem       Date:  2019-03-26       Impact factor: 5.157

4.  Oral hymecromone decreases hyaluronan in human study participants.

Authors:  Joelle I Rosser; Nadine Nagy; Riya Goel; Gernot Kaber; Sally Demirdjian; Jamie Saxena; Jennifer B Bollyky; Adam R Frymoyer; Ana E Pacheco-Navarro; Elizabeth B Burgener; Jayakumar Rajadas; Zhe Wang; Olga Arbach; Colleen E Dunn; Anissa Kalinowski; Carlos E Milla; Paul L Bollyky
Journal:  J Clin Invest       Date:  2022-05-02       Impact factor: 19.456

5.  Kinetics of hepatic transport of 4-methylumbelliferone in rats. Analysis by multiple indicator dilution method.

Authors:  S Miyauchi; Y Sugiyama; Y Sawada; K Morita; T Iga; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

6.  Inhibition of hyaluronan synthesis protects against central nervous system (CNS) autoimmunity and increases CXCL12 expression in the inflamed CNS.

Authors:  Andre Michael Mueller; Bo Hyung Yoon; Saud Ahmed Sadiq
Journal:  J Biol Chem       Date:  2014-06-27       Impact factor: 5.157

7.  The pharmacokinetics and dosing of oral 4-methylumbelliferone for inhibition of hyaluronan synthesis in mice.

Authors:  H F Kuipers; N Nagy; S M Ruppert; V G Sunkari; P L Marshall; J A Gebe; H D Ishak; S G Keswani; J Bollyky; A R Frymoyer; T N Wight; L Steinman; P L Bollyky
Journal:  Clin Exp Immunol       Date:  2016-09       Impact factor: 4.330

8.  Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer.

Authors:  Travis J Yates; Luis E Lopez; Soum D Lokeshwar; Nicolas Ortiz; Georgios Kallifatidis; Andre Jordan; Kelly Hoye; Norman Altman; Vinata B Lokeshwar
Journal:  J Natl Cancer Inst       Date:  2015-04-13       Impact factor: 13.506

Review 9.  4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer.

Authors:  Nadine Nagy; Hedwich F Kuipers; Adam R Frymoyer; Heather D Ishak; Jennifer B Bollyky; Thomas N Wight; Paul L Bollyky
Journal:  Front Immunol       Date:  2015-03-23       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.